================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                Date of Report (Date of earliest event reported):
                                  April 3, 2006

                               TRANSGENOMIC, INC.
             (Exact name of registrant as specified in its charter)

             DELAWARE                                          000-30975
       (State of Formation)                             (Commission File Number)

                                    911789357
                      (IRS Employer Identification Number)

         12325 Emmet Street
              Omaha, NE                                           68164
(Address of principal executive offices)                       (Zip Code)

                                 (402) 452-5400
              (Registrants' telephone number, including area code)

                                 Not applicable
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e(c))

================================================================================



ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
          APPOINTMENT OF PRINCIPAL OFFICERS

        Collin J. D'Silva has resigned as Chief Executive Officer of
Transgenomic, Inc. (the "Company"), effective April 3, 2006. Mr. D'Silva will
remain as the Chairman of the Board of Directors and will focus on managing
strategic customer relationships and the evaluation of corporate strategic
alternatives. Michael A. Summers, currently the Company's Chief Financial
Officer, has assumed the additional duties of Chief Executive Officer on an
interim basis until the search for a new Chief Executive Officer is completed.
Mr. Summers, 41, has served as the Company's Chief Financial Officer since
August 2004. Mr. Summers was employed with C&A Industries, Inc. from 2003 to
2004, where as General Manager he was responsible for the operations of various
divisions that provided human capital management and consulting services. From
2001 to 2003, Mr. Summers was Executive Vice President and Chief Financial
Officer for Nexterna, Inc., a wholly-owned technology subsidiary of Union
Pacific Corporation. From 2000 to 2001, Mr. Summers was the Chief Accounting
Officer for Able Telcom Holding Corp., a publicly-owned project management and
construction company. Mr. Summers services are provided to the Company under
terms of an existing employment agreement with an initial term of three years
expiring July 2007, and with base compensation equal to $200,000 per year.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) EXHIBITS.

99.1    PRESS RELEASE DATED APRIL 3, 2006.

        Press Release, dated April 3, 2006, announcing that Collin J. D'Silva
has resigned as Chief Executive Officer, effective April 3, 2006, and that
Michael A. Summers, currently the Company's Chief Financial Officer, has assumed
the additional duties of Chief Executive Officer on an interim basis until the
search for a new Chief Executive Officer is completed.

                                        2


                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                    TRANSGENOMIC, INC.


                                                    By /s/ Mitchell L. Murphy
                                                       ------------------------
                                                       Mitchell L. Murphy
                                                       VP, Secretary & Treasurer
April 4, 2006
                                       3